Meditech is an Australian biotechnology company focused on developing and commercialising drugs that improve the health and quality of life of patients with cancer and other chronic diseases. The company has internationally recognised expertise in carbohydrate-based therapies, particularly products based upon the glycosaminoglycan, hyaluronic acid. Building on this expertise, Meditech has created its patented HyACTTM (Hyaluronic Acid Chemotransport Technology) platform which it is applying to the development of improved formulations of cancer drugs. The lead product from the HyACTÔ platform is HyCAMPÔ. In addition to HyCAMPTM, Meditech has taken the anti-cancer products HyDOXTM (doxorubicin and hyaluronic acid) and HyFIVETM (5-fluorouracil and hyaluronic acid) into clinical testing.
| Website | http://www.mrl.com.au |
| Revenue | $14 million |
| Employees | 4 (3 on RocketReach) |
| Phone | +61 3 9296 2026 |
| Industry | Research, Biotechnology, Pharmaceuticals, Healthcare |
| Keywords | Drug Commercialization, Biotechnology, Drug Development, Pharmaceutical, Oncology, Cancer Treatment, Chronic Disease, Immunotherapy, Therapeutics, Biopharma, Health, Clinical Trials, Drug Discovery, Biologics, Healthcare, Patient Care, Medical Research, Pharmaceutical Research |
| Competitors | LafargeHolcim Europe, Air Products, CEMEX, Praxiar Inc, CIMBURKINASA, Drax Group, Climeworks, CarbonCure Technologies, Global CCS Institute, Carbon Clean +38 more (view full list) |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies |
Looking for a particular MIS.CARBONART employee's phone or email?
The MIS.CARBONART annual revenue was $14 million in 2026.
3 people are employed at MIS.CARBONART.
MIS.CARBONART is based in Perth, Western Australia.
The NAICS codes for MIS.CARBONART are [54, 541, 5417].
The SIC codes for MIS.CARBONART are [87, 873].